Optimal control strategies of eradicating invisible glioblastoma cells after conventional surgery

Journal of the Royal Society Interface

Volumn 12, Issue 106, 2015, Pages

  De Los Reyes V, Aurelio A ^a,b   Jung, Eunok ^b   Kim, Yangjin ^b,c  

^a Diliman   (Philippines)

^b Konkuk University   (South Korea)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Cell proliferation and invasion; Drug intravenous infusion; Glioblastoma multiforme; Glucose intravenous infusion; Optimal control theory

Indexed keywords

BIOELECTRIC POTENTIALS; CELL PROLIFERATION; CELLS; CONTROL SYSTEMS; CONTROL THEORY; CYTOLOGY; DISEASES; DRUG DOSAGE; DRUG INFUSION; GLUCOSE; METABOLISM; RNA; STRUCTURAL OPTIMIZATION; SURGERY;

CELL INFILTRATION; GLIOBLASTOMA CELLS; GLIOBLASTOMA MULTIFORME; INTRAVENOUS ADMINISTRATION; MICROENVIRONMENTS; OPTIMAL CONTROL STRATEGY; OPTIMAL CONTROL THEORY; SIGNALLING MOLECULES;

CELL SIGNALING;

ADENYLATE KINASE; ANTINEOPLASTIC AGENT; GLUCOSE; MICRORNA; MICRORNA 451; UNCLASSIFIED DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MIRN451 MICRORNA, HUMAN;

ARTICLE; BRAIN TISSUE; CANCER CONTROL; CANCER PATIENT; CANCER SURGERY; CELL INFILTRATION; CELL MIGRATION; CELLULAR DISTRIBUTION; CONTROL STRATEGY; DIABETIC PATIENT; GLIOBLASTOMA; GLIOMA CELL; GLUCOSE INFUSION; GLUCOSE INTAKE; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; OUTCOME ASSESSMENT; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; BRAIN NEOPLASMS; CELL MOTION; CELL SURVIVAL; COMPUTER ASSISTED DRUG THERAPY; COMPUTER SIMULATION; DOSE RESPONSE; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MINIMAL RESIDUAL DISEASE; PATHOLOGY; POSTOPERATIVE CARE; PROCEDURES; TREATMENT OUTCOME;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL MOVEMENT; CELL SURVIVAL; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMPUTER-ASSISTED; GLIOBLASTOMA; GLUCOSE; HUMANS; INFUSIONS, INTRAVENOUS; MICRORNAS; MODELS, BIOLOGICAL; NEOPLASM, RESIDUAL; POSTOPERATIVE CARE; TREATMENT OUTCOME;

EID: 84929492287     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2014.1392     Document Type: Article

References (50)

1. Chintala SK, Tonn JC, Rao JS. 1999 Matrix metalloproteinases and their biological function in human gliomas. Int. J. Dev. Neurosci. 17, 495-502. (doi:10.1016/S0736-5748(99)00010-6)
2. Furnari FB et al. 2007 Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21, 2683-2710. (doi:10.1101/gad.1596707)
3. Vander Heiden MG, Cantley LC, Thompson CB. 2009 Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033. (doi:10.1126/science.1160809)
4. Kim JW, Dang CV. 2006 Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 15, 8927-8930. (doi:10.1158/0008-5472.CAN-06-1501)
5. Gatenby RA, Gillies RJ. 2004 Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891-899. (doi:10.1038/nrc1478)
6. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P. 2005 Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 65, 613-621.
7. Godlewski J et al. 2010 MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol. Cell 37, 620-632. (doi:10.1016/j.molcel.2010.02.018)
8. Jones RG, Thompson CB. 2009 Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 23, 537-548. (doi:10.1101/gad.1756509)
9. Hardie DG. 2007 AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 8, 774-785. (doi:10.1038/nrm2249)
10. Viollet B, Horman S, Leclerc J, Lantier L, Foretz M, Billaud M, Giri S, Andreelli F. 2010 AMPK inhibition in health and disease. Crit. Rev. Biochem. Mol. Biol. 45, 276-295. (doi:10.3109/10409238. 2010.488215)
11. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart- Hines Z, Irie HY, Gao S, Puigserver P, Brugge JS. 2009 Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461, 109-113. (doi:10.1038/nature08268)
12. Zhou G et al. 2001 Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174. (doi:10.1172/JCI13505)
13. Bartel DP. 2009 MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233. (doi:10.1016/j.cell.2009.01.002)
14. Esquela-Kerscher A, Slack FJ. 2006 Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259-269. (doi:10.1038/nrc1840)
15. Godlewski J et al. 2008 Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 68, 9125-9130. (doi:10.1158/0008-5472.CAN-08-2629)
16. Lawler S, Chiocca EA. 2009 Emerging functions of microRNAs in glioblastoma. J. Neurooncol. 92, 297-306. (doi:10.1007/s11060-009-9843-2)
17. Singh PK, Mehla K, Hollingsworth MA, Johnson KR. 2011 Regulation of aerobic glycolysis 737 by microRNAs in cancer. Mol. Cell Pharmacol. 3, 125-134.
18. Song Y, Wang P, Zhao W, Yao Y, Liu X, Ma J, Xue Y, Liu Y. 2014 MiR-18a regulates the proliferation, migration and invasion of human glioblastoma cell by targeting neogenin. Exp. Cell Res. 324, 54-64. (doi:10.1016/j.yexcr.2014.03.009)
19. Guo M et al. 2014 miR-656 inhibits glioma tumorigenesis through repression of BMPR1A. Carcinogenesis 35, 1698-1706. (doi:10.1093/carcin/bgu030)
20. Yang TQ et al. 2014 MicroRNA-16 inhibits glioma cell growth and invasion through suppression of BCL2 and the nuclear factor-κB1/MMP9 signaling pathway. Cancer Sci. 105, 265-271. (doi:10.1111/cas.12351)
21. Ma J, Yao Y, Wang P, Liu Y, Zhao L, Li Z, Li Z, Xue Y. 2014 MiR-152 functions as a tumor suppressor in glioblastoma stem cells by targeting Krüppel-like factor 4. Cancer Lett. 355, 85-95. (doi:10.1016/j.canlet.2014.09.012)
22. Wang L et al. 2014 MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma. Oncotarget 5, 5416-5427.
23. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, Krichevsky AM. 2008 MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell Biol. 28, 5369-5380. (doi:10.1128/MCB.00479-08)
24. Shi L, Wang Z, Sun G, Wan Y, Guo J, Fu X. 2014 miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2. Neuromolecular Med. 16, 517-528. (doi:10.1007/s12017-014-8305-y)
25. Kim Y, Roh S, Lawler S, Friedman A. 2011 miR451 and AMPK mutual antagonism in glioma cell migration and proliferation: a mathematical model. PLoS ONE 6, e28293. (doi:10.1371/journal.pone.0028293)
26. Kim Y, Roh S. 2013 A hybrid model for cell proliferation and migration in glioblastoma. Discrete Contin. Dyn. Syst. Ser. B 18, 969-1015. (doi:10.3934/dcdsb.2013.18.969)
27. Kim Y. 2013 Regulation of cell proliferation and migration in glioblastoma: new therapeutic approach. Front. Oncol. 3, 53. (doi:10.3389/fonc.2013.00053)
28. Burger PC, Dubois PJ, Schold Jr SC, Smitch Jr KR, Odom GL, Crafts DC, Giangaspero F. 1983 Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J. Neurosurg. 58, 159-169. (doi:10.3171/jns.1983.58.2.0159)
29. Gaspar LE, Fisher BJ, Macdonald DR, LeBer DV, Halperin EC, Schold Jr SC, Cairncross JG. 1992 Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int. J. Radiat. Oncol. Biol. Phys. 24, 55-57. (doi:10.1016/0360-3016(92)91021-E)
30. Joshi HR. 2002 Optimal control of an HIV immunology model. Optimal Control Appl. Methods 23, 199-213. (doi:10.1002/oca.710)
31. Kwon HD. 2007 Optimal treatment strategies derived from a HIV model with drug-resistant mutants. Appl. Math. Comput. 188, 1193-1204. (doi:10.1016/j.amc.2006.10.071)
32. Jung E, Lenhart S, Feng Z. 2002 Optimal control of treatments in a two-strain tuberculosis model. Discrete Contin. Dyn. Syst. Ser. B 2, 473-482. (doi:10.3934/dcdsb.2002.2.473)
33. Whang S, Choi S, Jung E. 2011 A dynamic model for tuberculosis transmission and optimal treatment strategies in South Korea. J. Theor. Biol. 279, 120-131. (doi:10.1016/j.jtbi.2011.03.009)
34. Jung E, Lenhart S, Protopopescu V, Babbs C. 2008 Optimal control applied to a thoraco-abdominal CPR. Math. Med. Biol. 25, 157-170. (doi:10.1093/imammb/dqn009)
35. Jung E, Babbs CF, Lenhart S, Protopopescu VA. 2006 Optimal strategy for cardiopulmonary resuscitation with continuous chest compression. Acad. Emerg. Med. 13, 715-721. (doi:10.1111/j.1553-2712.2006.tb01709.x)
36. Farin A, Suzuki SO, Weiker M, Goldman JE, Bruce JN, Canoll P. 2006 Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis. Glia 53, 799-808. (doi:10.1002/glia.20334)
37. Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA. 2009 Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 27, 1082-1086. (doi:10.1200/JCO.2008.19.1098)
38. Crute BE, Seefeld K, Gamble J, Kemp BE, Witters LA. 1998 Functional domains of the alpha1 catalytic subunit of the AMP-activated protein kinase. J. Biol. Chem. 273, 35 347-35 354. (doi:10.1074/jbc.273.52.35347)
39. Aguda BD, Kim Y, Piper-Hunter MG, Friedman A, Marsh CB. 2008 MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc. Natl Acad. Sci. USA 105, 19 678-19 683. (doi:10.1073/pnas.0811166106)
40. Gantier MP et al. 2011 Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. Nucl. Acids Res. 39, 5692-5703. (doi:10. 1093/nar/gkr148)
41. De Gaetano A, Arino O. 2000 Mathematical modelling of the intravenous glucose tolerance test. J. Math. Biol. 40, 136-168. (doi:10.1007/s002850050007)
42. Powathil GG, Gordon KE, Hill LA, Chaplain MAJ. 2012 Modelling the effects of cell-cycle heterogeneity on the response of a solid tumour to chemotherapy: biological insights from a hybrid multiscale cellular automaton model. J. Theor. Biol. 308, 1-19. (doi:10.1016/j.jtbi.2012.05.015)
43. Gordon K. 2006 Mathematical modelling of cell-cycle-dependent chemotherapy drugs: implications for cancer treatment, PhD thesis, University of Dundee, UK.
44. Dhooge A, Govaerts W, Kuznetsov YA. 2003 Matcont: a Matlab package for numerical bifurcation analysis of ODEs. ACM TOMS 29, 141-164. (doi:10.1145/779359.779362)
45. Godlewski J, Bronisz A, Nowicki MO, Chiocca EA, Lawler S. 2010 microRNA-451: a conditional switch controlling glioma cell proliferation and migration. Cell Cycle 9, 2742-2748. (doi:10.4161/cc.9.14.12248)
46. Giese A, Bjerkvig R, Berens ME, Westphal M. 2003 Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. 21, 1624-1636. (doi:10.1200/JCO.2003.05.063)
47. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB. 2007 Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67, 6745-6752. (doi:10.1158/0008-5472.CAN-06-4447)
48. Wesseling P, Kros JM, Jeuken JWM. 2011 The pathological diagnosis of diffuse gliomas: towards a smart synthesis of microscopic and molecular information in a multidisciplinary context. Diagn. Histopathol. 17, 486-494. (doi:10.1016/j.mpdhp.2011.08.005)
49. Kim Y, Lawler S, Nowicki MO, Chiocca EA, Friedman A. 2009 A mathematical model for pattern formation of glioma cells outside the tumor spheroid core. J. Theor. Biol. 260, 359-371. (doi:10.1016/j.jtbi.2009.06.025)
50. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. 2011 The brain tumor microenvironment. Glia 59, 1169-1180. (doi:10.1002/glia.21136)